Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-FAPI PET/CT for Staging of Gastric and Gastro-esophageal Junction Cancer
2023-505916-40-01Phase 2Completed
- Sponsor
- Aalborg University Hospital
- Start
- Nov 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 68Ga FAPI-46 in gastric cancer (GC) and esophagogastric junction cancer, sponsored by Aalborg University Hospital. Primary endpoints: Diagnostic accuracy of FAPI PET/CT and FDG PET/CT vs histopathology, Impact of FAPI PET/CT on TNM staging vs conventional imaging and 2 more. Started Nov 2023; status: completed.
02
Drugs
68Ga FAPI-46
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on 2023-505916-40-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505916-40-01.